Kraig Biocraft Laboratories, Inc. (KBLB) intrinsic value & 10-year financials
Kraig Biocraft Laboratories, Inc. (KBLB) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.09
- Market cap
- $90.6M
- Revenue (FY2025)
- —
- Revenue growth (10-yr CAGR)
- 255.1%
- ROIC (10-yr avg)
- 64.5%
- Free cash flow (FY2025)
- -$1.8M
KBLB 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$3.6M | $0.00 | -$1.8M | — | 39.3% |
| FY2024 | — | -$3.4M | $0.00 | -$1.8M | — | 40.0% |
| FY2023 | — | -$3.0M | $0.00 | -$1.3M | — | 43.4% |
| FY2022 | — | -$3.8M | $0.00 | -$1.9M | — | 57.6% |
| FY2021 | — | -$8.0M | — | -$1.9M | — | 109.3% |
| FY2020 | — | -$5.0M | — | — | — | 81.0% |
| FY2019 | — | -$2.9M | — | -$1.2M | — | 62.6% |
| FY2018 | $401.6K | -$1.2M | — | -$246.5K | -239.0% | 25.7% |
| FY2017 | $97.3K | -$2.3M | — | -$760.7K | -2215.4% | 72.8% |
| FY2016 | $31.9K | -$3.1M | — | -$1.0M | -9246.0% | 112.9% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Kraig Biocraft Laboratories, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Kraig Biocraft Laboratories, Inc. has earned high returns on invested capital, averaging 64.5% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Kraig Biocraft Laboratories, Inc. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Kraig Biocraft Laboratories, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $0.00 per share.